Related Experiment Video
Updated: Apr 23, 2026
In vitro Mesothelial Clearance Assay that Models the Early Steps of Ovarian Cancer Metastasis
Published on: February 17, 2012
CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?
Luana Calabrò1, Giovanni Luca Ceresoli, Alessandra di Pietro
1Immunoterapia Oncologica, Dipartimento di Oncologia Medica, Istituto Toscano Tumori, Azienda Ospedaliera Universitaria Senese, Viale Mario Bracci n. 16, 53100, Siena, Italy, l.calabro@ao-siena.toscana.it.
Abstract:
No second-line treatment significantly prolongs the survival of malignant mesothelioma patients who have a high unmet medical need. Here, we comment on the therapeutic potential of cytotoxic T-lymphocyte-associated protein (CTLA)4-blockade by the anti-CTLA4 monoclonal antibody (mAb) tremelimumab of refractory malignant mesothelioma patients. We also focus on the critical role of an accurate tumor assessment in the course of treatment with immunomodulating mAb. Finally, treatment with potentially effective, second-generation checkpoint(s) inhibiting mAb, as well future combination strategies in this deadly disease, will be discussed.
Insights
Tremelimumab, an anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, shows therapeutic potential for malignant mesothelioma. Accurate tumor assessment is crucial for optimizing immunotherapy in this hard-to-treat cancer.
Area of Science:
- Oncology and Immunology
- Cancer Therapeutics
- Mesothelioma Research
Background:
- Malignant mesothelioma is an aggressive cancer with limited second-line treatment options.
- There is a high unmet medical need for effective therapies in refractory malignant mesothelioma.
- Immunotherapy, specifically checkpoint blockade, offers a promising avenue for treatment.
Purpose of the Study:
- To evaluate the therapeutic potential of tremelimumab, an anti-CTLA-4 monoclonal antibody, in malignant mesothelioma.
- To highlight the importance of accurate tumor assessment for immunomodulatory antibody treatments.
- To discuss future directions, including second-generation checkpoint inhibitors and combination strategies.
Main Methods:
- Review of existing literature and clinical data on tremelimumab and CTLA-4 blockade.
- Discussion of the role of tumor assessment in immunotherapy response.
- Exploration of emerging immunotherapeutic approaches for malignant mesothelioma.
Main Results:
- Anti-CTLA-4 blockade with tremelimumab demonstrates potential clinical benefit in refractory malignant mesothelioma.
- Tumor assessment is critical for patient selection and treatment monitoring in immunotherapy.
- Further research into novel checkpoint inhibitors and combination therapies is warranted.
Conclusions:
- Tremelimumab represents a potential second-line treatment for malignant mesothelioma.
- Personalized treatment strategies incorporating accurate tumor assessment are essential for immunotherapy success.
- Advancements in immunotherapy, including combination approaches, hold promise for improving outcomes in malignant mesothelioma.
More Related Videos
08:01Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012